For $10 billion, Merck is acquiring a promising healthcare company which is in the early stages of its growth. Key to its ...

Merck is making big pharma waves again with a $10 billion deal to acquire Verona Pharma, reports Colin Kellaher for the Wall ...

Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory ...

Pharmaceutical giant Merck is buying Verona Pharma, a company that concentrates its efforts on respiratory diseases, in an ...

U.S. drugmaker Merck is nearing a deal worth about $10 billion to buy Verona Pharma, a company focused on therapies for lung ...

Merck (MRK) is spending about $10 billion to acquire Verona Pharma (VRNA) as the company looks to fill future revenue gaps.

The New Jersey-based pharma has inked one of the biggest deals of the year in pursuit of a promising new way to treat COPD.

Merck & Co. is acquiring Verona Pharma PLC in a $10 billion deal that will expand the pharmaceutical giant’s portfolio of ...

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

Merck is acquiring Verona Pharma for $10 billion, gaining COPD drug Ohtuvayre as part of its strategy to offset Keytruda's ...

Merck & Co. is closing in on an approximately $10 billion deal to acquire respiratory drugmaker Verona Pharma, the Financial ...

Merck & Co expects a research-and-development charge of about $10.3 billion, or $4 per share, this year as the drugmaker accounts its deal for Prometheus Biosciences Inc as an asset acquisition ...